Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

Lead Cancer Stem Cell Product Candidate Enters Clinical Trials

REDWOOD CITY, Calif., Nov. 4 /PRNewswire/ -- OncoMed Pharmaceuticals, a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the successful completion of the final tranche of its Series B financing round, raising $93 million. This tranche brings the total Series B financing to $154 million. New investor Nomura Phase4 Ventures participated in the financing along with existing OncoMed investors.

Proceeds from the financing will support the advancement of OncoMed's proprietary cancer stem cell antibody programs, including lead compound OMP- 21M18 and a second antibody, through Phase II clinical trials. OncoMed investors include top-tier venture capital firms US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners, as well as its strategic collaborator, GlaxoSmithKline.

"We are pleased to have completed this financing and to add Nomura Phase4 Ventures to our highly-regarded list of investors," said Paul Hastings, OncoMed's President and Chief Executive Officer. "These funds provide the company with multiple years of operating cash, and will enable OncoMed to take two cancer stem cell antibody therapeutics through Phase II clinical trials, as well as to expand our monoclonal antibody pipeline."

"Cancer stem cells appear to be a promising target for cancer treatment and OncoMed is a leader in the discovery of anti-cancer stem cell antibodies. We are pleased to support their development efforts through this investment," said Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

OMP-21M18 Enters Human Clinical Trials

OncoMed's lead anti-cancer stem cell antibody, OMP-21M18, entered human clinical studies earlier this year with the initiation of a Phase I trial in patients with advanced solid tum
'/>"/>

SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... , , RESEARCH TRIANGLE PARK, ... announced a partnership with Max Healthcare to open a Phase I/IIa ... This proof of concept unit will allow Pharmaceutical, Biotech & Device ... process across multiple therapeutic areas quickly and with the highest quality. ...
... , AUSTIN, Texas, Sept. 23 TOPAZ Technologies, a ... industry, today announced it has 15 customers who have upgraded to ... is focused on the management and approval process for Institutional Animal ... to address the research and compliance needs of the IACUC, TOPAZ ...
... , , BOSTON, Sept. ... (Nasdaq: PRXL ) and a leading global life ... released its second annual study on the state of the ... PAREXEL Consulting analysis, contained in the new white paper entitled ...
Cached Biology Technology:Max Neeman International to Open Phase I/IIa Unit 2TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions 2PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 2PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 3PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 4PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 5
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... SAN FRANCISCO Feb. 18, 2010 TGen ... a strategic alliance that will help emerging companies ... Rondaxe, a drug development consulting company in Syracuse, ... through all phases of the drug development and ...
... An international consortium of scientists, including Universitat Autnoma ... genome of three species of parasitoid wasps of the ... information on the genetic mechanisms of evolution. It is ... pests and of insect-borne diseases, since parasitoid wasps bite ...
... possible to go to the store and buy a kit ... test? A University of Missouri researcher is developing a tiny ... than a human hair and could test bodily fluids for ... "Many disease-related substances in liquids are not easily tracked," ...
Cached Biology News:Rondaxe and TD2 form strategic drug development alliance 2Genome sequencing of 3 parasitoid wasp species 2Small liquid sensor may detect cancer instantly, could lead to home detection kit 2
... to rapidly and reliably amplify unknown genomic ... APAgene provides hassle-free, ready-to use components, at ... are provided in each kit. The Genome ... filling, localized cloning of genomic DNA, isolating ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Mol wt: average mol wt16,951.27 Da by calculation...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: